ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….

Slides:



Advertisements
Similar presentations
Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
Advertisements

1 Novel Oral Anticoagulants: Benefits and risks Matthew Moles, MD December 4, 2012 University of Colorado.
Newer Anticoagulants Drug Class Nicole N. Nguyen, PharmD Senior Clinical Pharmacist Health Care Services October 16, 2013.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Stroke prevention in atrial fibrillation
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.
Atrial Fibrillation Warfarin and its newer alternatives
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
Indications for Perioperative Bridging Ann McBride, M.D. UW Anticoagulation Service.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Secondary prevention after a TIA or ischemic stroke.
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
ACUTE CORONARY SYNDROME
Scenario 1 30 year old male Metal mitral valve replacement Lifelong warfarin Nimesulide following a wrist fracture Estimate the annual risk of GI bleed.
Adam M. Levine, DO, FACC Clinical Assistant Professor of Medicine Rowan University September 12 th, 2015.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
Antithrombotic Trialists’ Collaboration An updated collaborative overview of randomised trials of antiplatelet therapy among high-risk patients.
Anticoagulation ACCP guidelines 2012
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
WarfarinApixaban Primary outcome: major/clinically relevant bleeding (through 6 months) Secondary objective: Death, MI, stroke, stent thrombosis Randomize.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Rikki Weems, PGY III August 20, 2015
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Simon Howard Medical Management of Acute Stroke. Fast Recognition of Stroke With sudden onset neurological symptoms: 'FAST' should be used to screen for.
Nathan P. Clark, Pharm D, FCCP, BCPS Clinical Pharmacy Supervisor Clinical Pharmacy Anticoagulation and Anemia Service Kaiser Permanente Colorado Aurora,
Anticoagulation in Atrial Fibrillation Dalia Hawwass PGY2 June 2015.
Causes of Heart Valve Dysfunction Congenital defects (bicuspid aortic valve) Infections (rheumatic fever and bacterial endocarditis Coronary artery disease.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Outpatient DVT assessment & treatment Daniel Gilada.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Mike Kolber BSc, MD, CCFP, MSc AAPCE Nov. 3, 2012.
Cardiology Division, Jeju National University Hospital, Jeju, KOREA
You can never be too Thin…. An Update on NOACs
An approach to using risk scores for stroke and bleeding in clinical practice. An approach to using risk scores for stroke and bleeding in clinical practice.
Guide on how to manage atrial fibrillation in the office
Ortho Warfarin Dosing Protocol
Anticoagulation in Atrial Fibrillation
Ischaemic Heart Disease Acute Coronary Syndrome
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Atrial fibrillation (AF) and flutter
Oral Anticoagulation and Preventing Stent Thrombosis
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Barriers to Oral Anticoagulant Use for Stroke Prevention in AF
Glenn N. Levine et al. JACC 2016;68:
Fibrillazione atriale
Selecting NOACs for High-Risk Patients
TIA/Stroke (1) C.L.I.P.S. Why do we care?
Bridging Anticoagulation
Acute Coronary Syndrome (1)
Presentation transcript:

ANTI-COAGULATION

ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery …. 40 mg q day with initial dose given 2 hrs prior to surgery & continue 7-10 days Hip Replacement …… 30 mg q 12 hrs or 40 mg q day, with initial dose hrs after surgery, x 10 days or until risk is less or pt on warfarin for 35 days. Knee replacement ….. 30 mg q 12 hr or 40 mg q day, with initial dose after surgery for 10 days (some recommend 35 days) Mobility Restricted …. Either 30mg (crcl 30) q day…within 24 hrs after surgery, hx dvt, high risk DVT or Pulmonary embolism = 1mg/kg q 12hr or 1.6 mg/kg q day Pregnant women- 1mg/kg/dose q 12 hr. Stop >=24 hrs prior to induction of labor. Continue x >=6wks postpartum PCI – if pt has gotten enoxaparin < 8hrs ago, no additional enoxaparin needed. PCI- if pt has gotten enoxaparin 8-12 hrs previous.. Give single dose of 0.3 mg/kg x 1 PCI- if pt has gotten enoxaparin > 12 hrs previous. Give full dose. ST- elevation MI (STEMI) – 30mg iv bolus + 1mg/kg subq every 12 hrs. (max 100mg for first 2 doses). Additionally All pts should receive aspirin indefinitely and clopidogrel.

ENOXAPARIN Mechanical heart valve (aortic or mitral) to bridge therapy- 1 mg/kg q 12 hrs Unstable angina or non=ST elevation (NSTEMI) – 1mg/kg q 12hrs w asa for at Least 2 days or up to 8 days)

ATRIAL FIBRILLATION CHAD2 = CHF=1 HTN= 1 Age>=75 =1 DM=1 Stroke or TIA= 2 Chad 0= no therapy or aspirin mg / day CHAD1= OAC or aspirin mg/day (ACCP= prefers dabigatran over VKA) CHAD2= OAC (for high risk pts not considered candidates for OAC= aspirin+Clopido)

ACTIVASE - EXCLUSIONS Surgery within past 3 months HTN > 160/90 Outside hr therapeutic window On an anticoagulant Age > 80 YO HX Stroke & DM.

CARDIO-CONVERSION IN AF Thrombi present plus cardioversion = 91% stroke rate. AF for greater than 48 hours = 15% rate of atrial thrombus AF for greater than 72 hours= 30% rate of thrombus. Anticoagulant 3-4 weeks prior to conversion Anticoagulant for at least 4 weeks after conversion.

STROKE- TREATMENT WITH ACTIVASE Within 4.5 hours of symptom onset Dose 0.9 mg/kg IV, 90mg max, then 10% of it as bolus, rest given over 1 hour Improvement of symptoms Intracranial or subarachnoid bleed Other active bleed, intracranial surgery with past 3 months Major surgery in past 2 weeks, age > 80 GI or UT bleed in past 3 weeks, previous stroke combined with DM BP >185/110 or aggressive tx to lower bp Pregnancy, seizure, neoplasm, taking nother anticoagulant, Plts < 100k

STROKE-SECONDARY PREVENTION American Stroke Association recommends aspirin-dipyridamole or aspirin, or clopidogrel. (initiate aspirin mg after initial dose with mg q day within 48 hrs of stroke Use warfarin if Afib is associate with prosthetic heart valves.

STEMI (MI) TREATMENT (M) orphine 2-4 mg q 5-15 min prn (O) oxygen---- if O2 sats < 90% (N) itroglycerin (A) spirin chew and swallow mg Beta-blocker-start within 24 hrs Ace-inhibitor- start within 24 hrs Aldosterone antagonist Statin, nitrates, ccb

NSTEMI - TREATMENT Antiplatelet plus P2Y12 plus ASA PCI- balloon, stent implantation